• Anselm J Gadenstaetter, Lukas Schmutzler, Dirk Grimm, and Lukas D Landegger.
• Department of Otolaryngology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
• Transl Res. 2022 Oct 1; 248: 87-110.

AbstractAdeno-associated viruses (AAVs) represent some of the most commonly employed vectors for targeted gene delivery and their extensive study has resulted in the approval of multiple gene therapies to treat human diseases. The intranasal route of vector application in gene therapy offers several advantages over traditional ways of administration. In addition to targeting local tissue like the olfactory epithelium, it provides minimally invasive access to various organ systems, including the central nervous system and the respiratory tract. Through a systematic literature review, a total of 53 articles that investigated the intranasal application of AAVs were identified, included, and summarized in this manuscript. Within these studies, AAV-based gene therapy was mainly investigated for its application in various infectious, pulmonary, or neurologic and/or psychiatric diseases. This review gives a comprehensive overview of the current technological state of the art regarding the intranasal application of AAVs for gene transfer and discusses remaining hurdles, which still have to be resolved before this approach can effectively be implemented in the routine clinical setting.Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

10 keywords...

hide…